Salmon calcitonin in the therapy of corticoid-induced osteoporosis

Ringe, J. D.; Welzel, D

doi:10.1007/bf00610377

Cited by 150 publications

(53 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Information is available for bisphosphonates, fluoride and SERMs in postmenopausal osteoporosis. 80 For none of these treatments was there a significant difference when patients were stratified according to the presence or absence of prevalent vertebral fractures.…”

Section: Chaptermentioning

confidence: 99%

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Kanis¹,

Stevenson²,

McCloskey³

et al. 2007

Health Technol Assess

134

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Section: Chaptermentioning

confidence: 99%

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Kanis¹,

Stevenson²,

McCloskey³

et al. 2007

Health Technol Assess

134

View full text Add to dashboard Cite

show abstract

“…With a relative risk (RR) of 0.71 (95% CI: 0.26-1.89) for vertebral and 0.52 (95% CI: 0.14-1.96) for non-vertebral fractures, the risk of fractures was not significantly different between calcitonin and placebo. In patients with steroid-dependent, chronic obstructive lung disease and associated steroid-induced osteoporosis, calcitonin was shown to reduce back pain significantly versus untreated controls [115,116].…”

Section: Calcitoninmentioning

confidence: 99%

Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment

et al. 2006

View full text Add to dashboard Cite

“…Parenteral calcitonin, as an inhibitor of bone resorption, has produced a small increase in bone mass during 6 months in corticosteroid-induced osteoporosis, whist BMD decreased in controls [82]. No data on fracture rate are available.…”

Section: T Olbricht and G B E N K E Rmentioning

confidence: 99%

Glucocorticoid‐induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases

Olbricht

Benker

1993

Journal of Internal Medicine

View full text Add to dashboard Cite

Abstract. Olbricht T, Benker G (Department of Medicine, University ofEssen, Germany) Glucocorticoid-induced osteoporosis : pathogenesis, prevention and treatment, with special regard to the rheumatic diseases (Review). lournal of Internal Medicine 1993: 234: 237-244.Objectives. To review factors associated with development of osteoporosis in patients with rheumatic diseases, as well as the preventive and therapeutic measures. Design. A MEDLINE literature search. Results. 1 Pathogenesis. Rheumatoid arthritis in itself causes reduction of bone mass; this process can be aggravated by glucocorticoid treatment. With glucocorticoid treatment, bone mineral density decrease is most pronounced during the first months of treatment. There is no agreement on the effects of daily dose, cumulative dose, and duration of glucocorticoid treatment on the rate of bone loss. However, with treatment by low doses ( < 1 0 m g of prednisone equivalent per day), bone loss appears to be minimal or even undetectable compared to controls. Alternate day treatment, or treatment with steroid 'pulses' have not been shown to protect from bone loss. 2 Prevention and treatment. Prophylactic and therapeutic measures for glucocorticoid-induced osteoporosis include calcium supplementation, vitamin D in physiological doses and oestrogen in perimenopausal female patients. Efficacy has not always been shown in this particular indication but is extrapolated from other forms of osteoporosis. Limited data exist on treatment with anabolic steroids, calcitonin (with an additional analgesic effect) and biphosphonates and reduction of fracture rates has not yet been investigated. At present, there is insufficient evidence to show that altered steroid molecules can dissociate adverse effects on bone from clinically desirable effects. Conclusion. In view of the paucity of study data, prophylaxis and therapy of glucocorticoid-induced osteoporosis should receive more attention in future clinical studies.

show abstract

Salmon calcitonin in the therapy of corticoid-induced osteoporosis

Cited by 150 publications

References 14 publications

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment

Glucocorticoid‐induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases

Contact Info

Product

Resources

About